Among anti-IL-17 biologic agents, inhibitors, for the treatment of psoriasis are available ixekizumab and secukinumab, which are IL-17A inhibitors; brodalumab, an inhibitor of the IL-17A receptor; and bimekizumab, a monoclonal IgG1 antibody that inhibits both IL-17A and IL-17F [2]. The gene discussed is IL17A; the disease is psoriasis.